IPSEN SA S/ADR (IPSEY) analyst actions
Rating and price-target actions on IPSEY in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the IPSEY overview →
5 measured IPSEY analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance | Press release | +0.00% | -2.20% | |
| Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance | Press release | — | — | |
| Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III | Press release | — | — | |
| Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance | Press release | — | — | |
| Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance | Press release | +0.00% | +0.00% |
Keep exploring
More IPSEY: earnings → · SEC filings → · IPSEY overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | 296 | -0.65% | 35% |
| Processa Pharmaceuticals, Inc. (PCSA) | 296 | 0.00% | 50% |
| Adicet Bio, Inc. (ACET) | 293 | -0.83% | 36% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 293 | +0.08% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.